Multiple studies have shown the association between the dysregulation of the BDNF signaling pathway and the development and progression of depression and cognitive decline [25,26,27,30,31], both of which are frequently diagnosed comorbidities in OSA patients. This evidence concerns the gene BDNF and depressive disorder.